Shots:
- Zenas BioPharma has entered into an agreement with Royalty Pharma granting it royalty rights on the future sales of obexelimab
- As per the deal, Zenas will receive ~$300M, consisting of a $75M upfront & 3 additional $75M each in milestones tied to P-III (INDIGO) trial achievement & FDA approvals in IgG4-RD & SLE, while Royalty Pharma will earn a 5.5% royalty on global obexelimab sales. Financing will support development & potential IgG4-RD launch in H1’27, pending approval
- Obexelimab, a bifunctional mAb targeting CD19 & FcγRIIb, is being evaluated in P-III trial for IgG4-RD (topline data expected by 2025 end) & P-II for relapsing multiple sclerosis (data expected by Q4’25) & systemic lupus erythematosus (data expected by mid-2026)
Ref: Zenas | Image: Royalty Pharma and Zenas | Press Release
Related News:- Royalty Pharma Signs Agreement to Acquire Interest in Amgen’s Imdelltra Royalties from BeOne Medicines for ~$950M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
